Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Matthew Steele

Sports Medicine Phoenix, AZ Doctor of Osteopathy

NPI 1407218860 CMS profile 8803723

1320 N 10Th St Ste B, Phoenix, AZ 85006

Open in the dashboard

General payments

$8,582

23 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Steele of Phoenix, AZ is reported in the CMS Open Payments database as having received $8,582 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,910 13
2024 General $169 4
2023 General $14 1
2021 General $31 3
2020 General $2,459 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Steele
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Matthew Steele were reported at $5,910. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Matthew Steele Sports Medicine median Middle half National median
2019 $0 $119 $35–$362 $163
2020 $2,459 $77 $24–$275 $114
2021 $31 $104 $28–$340 $132
2022 $0 $94 $31–$272 $149
2023 $14 $91 $34–$271 $160
2024 $169 $126 $38–$294 $164
2025 $5,910 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Trice Medical, Inc. $5,854 9 payments
  2. Goode Surgical Inc $2,459 2 payments
  3. Nalu Medical, Inc. $89 1 payment
  4. Bioventus LLC $80 4 payments
  5. Ferring Pharmaceuticals Inc. $35 2 payments
  6. ImpactOrtho, Inc. $34 2 payments
  7. Orthofix Medical, Inc. $31 3 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $3,150 2 payments
  2. Education $2,441 1 payment
  3. Travel and Lodging $2,145 1 payment
  4. Food and Beverage $846 19 payments
Products named General payments · program years 2020–2025
  1. Nalu Neurostimulation System $89 1 payment
  2. EXOGEN ULTRASOUND BONE HEALING SYSTEM $80 4 payments
  3. EUFLEXXA $35 2 payments
  4. Physio-Stim $31 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

301

Median for General Practice: 1,105

Drug cost

$3,183

Median for General Practice: $48,734

Branded share of claims

10%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 57 $1,067
Baclofen Generic 24 $577
Gabapentin Generic 55 $563
Diclofenac Sodium Generic 29 $397
Naproxen Generic 22 $186
Cyclobenzaprine Hcl Generic 17 $107
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 30 $106
Methylprednisolone Generic 13 $88
Tramadol Hcl Generic 42 $65
Meloxicam Generic 12 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$114,629

Of which drugs: $18,756

Medicare patients

423

Average age 74

Services billed

3,258

258 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Ischemic heart disease 25%
Chronic kidney disease 25%
Diabetes 24%
Depression 18%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 37 171 $16,357
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 145 904 $656
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 63 851 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record